🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Just out 📢 all you need to know about #MRD in Ph-positive ALL: high-sensitivity NGS-based assay for IG/TCR vs. standard of care #PCR for BCR::ABL1 ▶️ Which test is better🤔? #leukemia #leusm #ALL #research MD Anderson Cancer Center Nicholas Short MD Walid Macaron, MD MSc Hagop Kantarjian,MD

If you will be at #ASCO23 please join Hagop Kantarjian,MD, Dr. Elias Jabbour and me on June 3rd at 7PM at the Radisson Blue Aqua Hotel for discussion on Optimizing Frontline Treatment Selection in Ph+ #ALL.

We are proud to celebrate our Dr. Hagop Kantarjian receiving the prestigious David A. Karnofsky Memorial Award from ASCO for his contributions to leukemia care and research. Hagop Kantarjian,MD #ASCO23 #EndCancer [1/3]

The lifestory of Prof Hagop Kantarjian,MD: an inspiring showcase of his efforts that has changed the face of leukemia therapy over the last 4 decades. Conferred today the David Karnofsky Award (highest award by ASCO). So fortunate to learn from him and have him leading us 🙏🏼

What a pleasure working on this multi-center effort with dear friends/colleagues under the mentorship of Toni Choueiri, MD Rafeh Naqash, MD Edward El-Am, MD Ryan Denu, MD, PhD Sarah Abou Alaiwi Talal El Zarif, MD Elias Bou Farhat Rana McKay, MD, FASCO Omar Chehab, MD, MSc Jennifer Kwan MD PhD george demetri Clinical Outcomes

Aza + ven + gilteritinib highly effective in newly dx older FLT3-mut #AML: CR/CRi 96% and 18-month OS 72%. A new standard of care in this population. Nicholas Short MD of MD Anderson Cancer Center #Leukemia ascopubs.org/doi/10.1200/JC… Journal of Clinical Oncology #leusm

Our paper on aza + ven +gilteritinib for FLT3mut #AML now online at Journal of Clinical Oncology In frontline FLT3mut AML, CR 90% (vs. 30-50% with aza+ven) and 18mo OS 72% (vs. 2yr OS 20-40% with aza+ven) Could be delivered safely with appropriate dose modifications. ascopubs.org/doi/10.1200/JC…

Adding gilteritinib to azacitidine and venetoclax shows improved outcomes in patients with FLT3-mutated acute myeloid leukemia, according to a study led by MD Anderson researchers. bit.ly/3SjKX4f Nicholas Short MD Hagop Kantarjian,MD Naval Daver, M.D. Tapan Kadia #AML #EndCancer

Although immune checkpoint inhibitors demonstrate modest activity in cardiac soft tissue sarcomas, durable benefit was observed in a subset of patients w/ nonangiosarcoma, albeit w/ higher toxicity. bit.ly/3OvJiYD #JACCCardioOnc #CardioOnc #Immunotherapy Amin Nassar, MD

🫀Don't miss this original research from a great team in JACC Journals! 📰tinyurl.com/bu4kxxnf Amin Nassar, MD Toni Choueiri, MD george demetri Tomas G. Neilan, MD, MPH Aakash Desai, MD, MPH, FASCO Hanna Dalla Pria, MD Ryan Denu, MD, PhD #JACCCardioOnc

CONGRESS #ASH24 | PRESENTATION Walid Macaron, MD MSc, MD Anderson Cancer Center and BCMHouston discussed achievement of MRD negativity and positive long-term outcomes in B-ALL. In pts with PH- B-ALL , 2-yr RFS was higher in pts who were MRD neg after cycle 1, vs those who were pos after cycle 1.

Our ⁦Texas Medical Center⁩ before WWII and today (my photo from a Southwest Airlines flight). Today our Texas Medical Center in Houston is the world’s largest, and also the first biomedicine city of >100,000 employees, >60 institutions, including several medical schools

Our new paper in Journal for ImmunoTherapy of Cancer with a group of fine international friends, mentees and colleagues about immunotherapy in patients with cardiac metastasis. jitc.bmj.com/content/13/3/e… Rafeh Naqash, MD Amin Nassar, MD Sarah Abou Alaiwi Talal El Zarif, MD Rana McKay, MD, FASCO Dana-Farber

‼️Only data so far of ICI in pts with cardiac Mets. Work led by Amin Nassar, MD Sarah Abou Alaiwi Talal El Zarif, MD out in Journal for ImmunoTherapy of Cancer . A collaboration that spanned several countries and centers. OU College of Medicine OU Health Stephenson Cancer Center Toni Choueiri, MD jitc.bmj.com/content/13/3/e…

Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study out on JITC buff.ly/iFnRFbO This retrospective, multicenter study examined the safety and clinical outcomes of 110

Expert recommendations on using MRD in #ALL now out in Blood Advances. ClonoSEQ (NGS MRD) is superior to other MRD methods and should guide decisions about CAR T-cells or SCT MD Anderson Cancer Center #Leukemia doi.org/10.1182/blooda… #leusm